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Abstract  
Background: Coronary artery disease (CAD) can be managed with Percutaneous Coronary  
Intervention (PCI) or Coronary Artery Bypass Grafting (CABG). Management of subtypes of 
CAD, including Multivessel Disease (MVD) and isolated Left Main Coronary Artery (LMCA) 
disease, continue to evolve in the literature. An observational registry may provide 
implications for management of CAD.  
  
Methods: All isolated LMCA and triple-vessel disease patients who received either PCI or 
CABG in Newfoundland & Labrador (NL) were analyzed in two separate studies. The first study 
evaluated isolated LMCA patients for freedom from Major Adverse Cardiac Events (MACE). 
The second study evaluated triple vessel disease patients for in-hospital mortality post 
revascularization. 
  
Results: Firstly, 115 patients with isolated LMCA disease (n=7 PCI, n=99 CABG, n=9 medical 
management) were identified from May 2006 to October 2015. The rate of MACE at 1 year was 
5.1% in the CABG cohort. Secondly, a total of 1604 triple vessel disease patients (n=45 PCI, 
n=1559 CABG) were analyzed with a median follow up of 5.4 years. The in-hospital mortality 
rate was 2.2% and 1.2% in the PCI and CABG cohorts, respectively (p=0.533).  
  
Conclusion: CABG represented the most common revascularization strategy for both study 
populations. Freedom from MACE at one year in the CABG isolated LMCA patients was 
comparable to the literature. Early survival rates were comparable in low-risk triple vessel 
disease patients revascularized with either therapy and further evaluation is warranted to account 
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General Summary   
Cardiac research has been a personal interest of mine for several years now. This project 
was created to further understand the treatment of heart disease, specifically Coronary Artery 
Disease (CAD), in Newfoundland and Labrador (NL). There are many large studies that have 
looked at the treatment of CAD over the years; however, there is limited research on our local 
population. NL offers a unique opportunity to study treatment of CAD because the entire 
population is treated at the Health Science Center in St. John’s. Prior to receiving treatment for 
CAD, every patient must have a Cardiac Catheterization (also known as an angiogram or “dye 
test”). Therefore, this allows us to study every patient with CAD and see what treatment they 
received, which is either a stent placement or open-heart surgery typically. The data at our 
hospital allowed us to better understand how we are treating our population and what we can 
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Chapter 1: Introduction and Overview  
1.1 Background  
1.11 Coronary Artery Disease  
Coronary artery disease (CAD), also known as ischemic heart disease or coronary heart 
disease, is a condition that results in a reduction of blood flow through the arteries that supply the 
heart. The sequelae of CAD include a lack of essential nutrients and oxygen supply to the muscle 
of the heart that are responsible for generating cardiac output and systemic blood flow. A 
reduction in blood flow to these muscles can result in damage and subsequent death of those 
cells. The reduction in blood flow itself is a result of atherosclerosis, which is the deposition of 
cholesterol plaques on the interior wall of the coronary vessels. This cholesterol-based mass 
propagates on the arterial wall through a series of biochemical processes that are multifactorial in 
their etiology (Libby & Theroux, 2005). The resulting plaque can proceed to grow as a thrombus 
and occlude the vessel from which it originated, or it can embolize and migrate to a smaller 
vessel, often resulting in an acute occlusion and myocardial infarction (Libby & Theroux, 2005). 
The resulting symptoms of coronary artery disease often include angina pectoris (either with 
exertion or at rest), shortness of breath, general fatigue and radiation of pain into areas such as 
the arms, jaw, or back (Ashley EA & Niebauer J., 2004). CAD is a major cause of morbidity and 
mortality in the modern era and is a major issue in cardiac medicine as it continues to affect a 
large proportion of the population around the globe.     
  
1.12 Epidemiology of Coronary Artery Disease   
The World Health Organization (WHO) recognizes ischemic heart disease CAD as the 
leading cause of death worldwide, and thus this disease poses a significant burden on the general 
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population (WHO, 2015). In 2013, there were approximately thirty-four thousand deaths due to 
CAD in Canada (Statistics Canada, 2013). Epidemiologically, CAD has been a topic of 
discussion since the early 20th century and several risk factors have been identified, varying by 
population (Wong 2014). The first major study to identify risk factors for CAD was the Seven 
Countries Study (Keys 1980), and a forty-year follow up analysis of the original participants 
revealed that age, smoking habits, total cholesterol, and BMI were significant predictors of 
mortality in the population that was studied (Pitsavos et al., 2003). The multitude of 
epidemiological studies assessing the various risk factors for CAD led to various population level 
approaches of primordial, primary, and secondary prevention of CAD around the world (Wong 
2014). This project will focus on the secondary prevention of complications that arise from 
patients who have been diagnosed with CAD, such as MI, stroke, and cardiac mortality.   
  
1.13 Classifications of CAD  
The anatomy of the heart is structured through a four-chamber system that assists in the 
flow of blood for oxygenation in the lungs and then systemic circulation for the rest of the body. 
The muscles of the heart are constantly working and thus demand a constant blood flow 
throughout the organ in order to maintain function. The cardiac blood flow is achieved through 
the main coronary vessels (Figure 1), which include the left main coronary artery (LMCA), the 
left anterior descending artery (LAD), the circumflex artery (LCx), and the right coronary artery 
(RCA). The intricate branching system of these vessels supply the muscles of the heart and are a 
delicate system that poses a high risk for complication if they are occluded. Pathologically, 
atherosclerosis can affect any number of these vessels in various ways including partial or diffuse  
occlusion and complete occlusion. Therefore, there are multiple types of CAD that have different  
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Figure 1: Major coronary vasculature of the heart. Depicted above are the main branches of coronary arteries and 
the areas of the heart that they supply. LMCA = Left Main Coronary Artery, LCxA = Left Circumflex Artery, LAD = 
Left Anterior Descending Artery, RCA = Right Coronary Artery. Used with permission from Emily Pittman ©. 
 
indications for treatment and different prognoses. Understanding the underlying pathology of a 
given patient’s CAD is a vital component of the immediate and long-term management. 
Typically, to determine the extent of a patient’s pathology, a coronary angiogram is required. The 
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coronary angiogram procedure requires an interventional cardiologist to guide a catheter through 
the radial or femoral artery retrogradely to the coronary vasculature, subsequently injecting a dye 
to image the site(s) of the lesion(s). This procedure allows the disease pathology to be accurately 
evaluated allowing for accurate classification of CAD. Coronary angiograms have been shown to 
provide significant prognostic information, including left ventricular function, number of 
diseased vessels and number of diseased proximal artery segments, that enable an effective 
patient risk profile to be established (Ringqvist et al., 1983).   
The major category of interest for this project is triple-vessel CAD, which is defined as at 
least one occlusion in all three major coronary systems (LAD, LCx, and RCA). Another 
classification of CAD that will be discussed is isolated LMCA disease, defined as an occlusion in 
the LMCA with no other vessels significantly affected. Each of the aforementioned presentations 
have a unique set of risk factors to consider when deciding on management. A major objective of 
this project is to provide insights on various management strategies for triple vessel disease and 
LMCA disease in the Newfoundland and Labrador population.    
  
1.14 Management of CAD  
CAD has a variety of presentations and risk factors that must be considered when 
establishing a treatment plan for any given patient. Recent guidelines indicate that following 
patient education, a medical management plan may include statins (cholesterol-lowering drugs) 
and anti-hypertensives including ACE-inhibitors, beta-blockers, and calcium channel blockers 
(Finn et al., 2012).  Chronic and acute patient presentations are managed differently, with 
presentations of acute coronary syndromes often resulting in intervention via revascularization.  
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Coronary revascularization, via coronary artery bypass grafting (CABG) or percutaneous 
coronary intervention (PCI) is recommended as a class one indication in patients with significant 
stenosis in one or more major cardiac arteries despite treatment with the guideline-recommended 
medical therapy (Finn et al., 2012). CABG is a surgical technique that involves using a 
peripheral vessel, such as the saphenous vein or internal mammary artery, as a graft to create a 
route that bypasses the site of the occlusion, thereby allowing the vessel to regain normal blood 
flow to the affected heart muscle. CABG was initially introduced as a coronary revascularization 
technique in 1967 (Favaloro, 1967). Patients with complex comorbidities, poorly controlled risk 
factors for cardiac disease, and multivessel involvement are said to have severe disease. CABG 
grew in popularity for CAD management, especially in those considered to have severe disease. 
Initial clinical trials demonstrated long-term survival advantages associated with surgery among 
high severity patients when compared to medical management alone (Varnauskas et al., 1982; 
Detre et al., 1984). However, the development of PCI in 1978 (Gruntzig, 1978) prompted the 
need for more conclusive evidence regarding each respective coronary revascularization. PCI is a 
less-invasive technique that involves accessing the arterial vasculature via a peripheral vessel, 
such as the femoral or radial artery, and introducing a catheter with a balloon tip inside the vessel 
to the site of the occlusion. Once the occlusion site is reached via fluoroscopy, the balloon is 
expanded to revascularize the site of occlusion from within. Furthermore, modern methodology 
involves using stents instead of a balloon as an alternative option. PCI can now be used in a 
variety of presentations as an alternative to CABG therapy (Finn et al., 2012). Although CABG 
has been the gold standard for most forms of CAD, PCI is a less-invasive technique with fewer 
short-term risks to the patient and is therefore an important consideration for management of 
CAD. Furthermore, PCI presents a presumptive cost-effective strategy to revascularize patients 
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with CAD. The discussion on indications for either PCI or CABG has been ongoing for several 
decades resulting in a dense base of literature from which to draw guidelines for CAD 
management.  
  
1.15 Progression of trials evaluating CAD management  
The vast literature on CAD management indicates there is a constant evolution of 
therapeutic options available and accordingly, several studies have been published in the field  
(Appendix A). When discussing the management of multivessel CAD, there are three “eras” of 
coronary revascularization trials that are established in the literature. The progression from one 
era to another is a result of newer techniques in surgical and stent-based management over the 
years which warranted updated literature. The vast majority of publications in coronary 
revascularization are Randomized Controlled Trials (RCTs) that directly compare the two major 
therapeutic options: PCI and CABG.    
Approximately 4% of all patients undergoing coronary angiography are diagnosed with 
left main coronary artery disease (LMCA) and of these <20% have isolated LMCA (Fihn et al., 
2014)..  
Historically, isolated LMCA has been treated exclusively with coronary artery bypass graft 
(CABG) surgery (Buszman et al., 2008). The EXCEL (Stone et al., 2016) trial revealed 
comparable long-term rates of major adverse cardiac or cerebrovascular events (MACCE) 
following revascularization with either CABG or PCI for LMCA, while the NOBLE Makikallio 
et al., 2016) trial reported a significantly higher long-term rate of MACCE associated with PCI.   
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Clinical questions regarding optimal conduit selection for CABG, the need for 
quantitative assessment via intravascular ultrasound (IVUS) or Fractional Flow Reserve (FFR), 
and long term follow up remain understudied in the LMCA population. Moreover, the bilateral 
internal mammary arterial (BIMA) grafts conduit strategy remains underutilized in CABG 
patients (Windecker et al., 2014; Iribarne et al., 2017). In addition to isolated LMCA disease 
patients, multivessel disease patients have been studied extensively in the literature as well.  
Initial RCT evaluations of PCI and CABG compared balloon angioplasty to conventional  
CABG surgery; however, no definitive conclusions were drawn (Rodriguez et al., 1993;  
Hampton et al., 1993; King et al., 1994; Ham et al., 1994; Chaitman et al., 1997; Carrie et al.,  
1997). Limitations of these initial trials included loss to follow-up, underpowered design due to 
sample size, and outdated procedural methodology. Although there was a general trend towards a 
significantly fewer number of patients with angina and fewer patients requiring a subsequent 
revascularization associated with CABG, the primary outcomes from these trials were 
nonsignificant and thus these secondary findings were limited to hypothesis-generating 
speculation (Rodriguez et al., 1993; Hampton et al., 1993; King et al., 1994; Ham et al., 1994; 
Chaitman et al., 1997; Carrie et al., 1997). One of the more notable findings from this early era 
of revascularization trials was the significance of diabetes as a poor prognostic factor for PCI. 
Chaitman and colleagues demonstrated that there is a significantly increased risk of cardiac 
mortality in diabetic patients in the long-term (median follow up = 5.4 years; Chaitman et al., 
1997). This finding continues to play a significant role in current management of patients with 
CAD and comorbid diabetes mellitus.   
The development of bare-metal stents (BMS) in the late 1990s resulted in a new series of  
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RCTs comparing the updated PCI methodology to CABG (Serruys et al., 2001; Rodriguez et al., 
2001; SoS investigators, 2002; Heub et al., 2010). The trials in this era were well designed and 
led to many of the mainstays of coronary revascularization that are fundamental in modern 
practice. The general consensus remained that CABG is associated with superior long-term 
outcomes, despite a higher immediate post-operative risk, with a consistent finding that PCI is 
associated with significantly higher occurrences of subsequent revascularizations (Serruys et al., 
2001; Rodriguez et al., 2001; SoS Investigators, 2002; Heub et al., 2010).  
In accordance with the constant evolution of coronary revascularization, newer 
techniques such as drug-eluting stent (DES) placement and hybrid coronary revascularization 
were developed and necessitated more clinical trials (Htay & Liu, 2005; Riess et al., 1998). In 
fact, a recent meta-analysis demonstrated that patients with a DES PCI had significantly better 
outcomes than those with a BMS PCI (Pandya et al., 2010). Several well-designed RCTs 
evaluated various outcomes following either drug-eluting PCI or CABG surgery; however, the 
results remained dependent on the specific population being studied in addition to the 
significance of the primary outcome being driven by subsequent repeat revascularization 
procedures (Serruys et al., 2009; Farkouh et al., 2012; Kamelesh et al., 2013; Park et al., 2015).   
One of the most notable trials in the drug-eluting stent era is the SYNTAX trial, 
conducted by Dr. Patrick Serruys and colleagues (Serruys et al., 2009). The results from this 
large multi-centre trial revealed a significant reduction in the occurrence of major adverse cardiac 
or cerebrovascular events (MACCE) at 12 months in patients treated with CABG compared to 
those treated with PCI (p=0.002) (Serruys et al., 2009). Furthermore, a subgroup analysis 
revealed the utilization of a SYNTAX score based on pre-procedural anatomical severity had 
significant predictive value with respect to the occurrence of future MACCEs (Serruys et al., 
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2009). This significant finding resulted in the ability to predict negative outcomes based on 
severity of disease prior to reaching a treatment decision. Thus, high score patients could be 
confidently sent to surgery while low score patients could receive a stent or surgery depending 
on patient preference and physician recommendation. The SYNTAX trial remains one of the 
most influential studies in this field and underpins CAD management today. 
The decision to treat multivessel disease patients with either CABG or PCI however 
remains the subject of ongoing research. The Canadian Cardiovascular Society (CCS) indicates a 
strong quality of evidence in favor of CABG for high severity MVD presentations and a strong 
quality of evidence indicating no significant advantage for either treatment in low severity MVD 
presentations based on the SYNTAX scoring system (Teo et al., 2014). American guidelines also 
recommend a heart-team approach (vs single consultant approach) for determining the optimal 
revascularization strategy for various clinical presentations of different patients (Finn et al.,  
2012). The American and Canadian guidelines both outline the importance of the SYNTAX 
score in evaluating the risk for a patient undergoing an interventional revascularization 
procedure.  Despite this, there remains limited comparative literature of triple vessel disease 
patients that are both determined low risk via SYNTAX score and are completely revascularized 
(via either PCI or CABG).  
  
1.16 Gaps in Literature  
The literature on coronary revascularization is evidently vast and covers a wide range of 
topics. RCTs are widely accepted as the most effective way to evaluate treatment efficacy 
questions and thus the guidelines for CAD management are generally based on the outcomes and 
conclusions of RCTs (Teo et al., 2014). Despite the strength of the literature and RCT study 
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designs, there is an indication for critical validation of the present guidelines through evaluation 
of a real-life population in a non-interventional manner. The population in NL offers a unique 
opportunity to retrospectively evaluate outcomes in coronary revascularization due to the full 
ascertainment of the population through a tertiary referral catheterization laboratory. A study of 
this type is warranted to retrospectively evaluate revascularization outcomes in a population that 
is completely captured. Furthermore, an emphasis on outcome assessment in low-risk patients 
with complete revascularization achieved has been limited in the literature.  
The Newfoundland & Labrador population therefore offers a unique opportunity to study 
a subset of the Canadian population and evaluate the effectiveness of a small-moderate volume 
centre in the management of CAD patients. There are no previous studies comparing outcomes 
following PCI or CABG in triplevessel disease patients in the NL population. Given that NL is a 
founder population, with high rates of some genetic cardiac diseases causing Sudden Cardiac 
Death (SCD; Merner et al., 2008) and an apparently higher rate of SCD compared to Ontario 
unrelated to environmental issues such as BMI and smoking (Hamilton, 2016), it is reasonable to 
consider the possibility this population will differ from the overall general population represented 
in the larger clinical trials. Furthermore, there is a continued need for studies in this area of 
research, evident through the continuous publication of studies over the past three decades 
(Appendix A). This study aims to provide a benchmark for mortality and morbidity statistics for 
NL specifically, but data derived may also be useful for other medium-volume centres, similar to 
the Health Science Centre, when managing multivessel CAD. There has been little written on 
low-risk triple vessel disease populations, defined by those with low SYNTAX scores, who 
undergo complete coronary revascularization and the data from APPROACH offers the 
opportunity to assess this specific population. Moreover, data on secondary outcomes such as the 
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effectiveness of which vessels to use as a graft within CABG procedures and LMCA disease 
management can also be assessed with the data from APPROACH. Physicians and health care 
teams are faced with a wide range of MVD patients with various co-morbidities and 
environmental influences (lifestyle, socioeconomic status, etc.) on a regular basis. Therefore, the 
continued evaluation of MVD treatment remains an important topic and ongoing research is 
needed to support and update policy and guidelines in NL.  
 
1.2 Area of Investigation  
The setting of this project is at the Health Science Centre in St. John’s, NL (Figure 2). 
This Canadian province operates a tertiary referral centre in the capital city of St. John’s and 
treats cardiac patients from the entire province. Therefore, there is a unique opportunity to obtain 
clinical outcomes and complete follow up information on a fully ascertained population. All 
cardiac patients therefore requiring revascularization are assessed at the cardiac catheterization 
laboratory in St. John’s and their clinical data is collected and stored by trained professionals. 
The Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease 
(APPROACH) database has been active in NL since 2006 and contains clinical data on all 
cardiac patients from the point of catheterization onwards. Once a patient presents at the 
catheterization laboratory, they are assigned an APPROACH ID number that links with their 
provincial health records. Therefore, the APPROACH database can be screened for patients of 
various presentations, such as valvular heart disease, CAD, LMCA disease, etc. This annually 
populated prospective database offers a unique opportunity to conduct retrospective studies on 
patient outcomes and clinical care in NL over the past ten years allowing for complete 
assessment.  




Figure 2: Map of Newfoundland & Labrador, Canada. Image obtained from the public domain at 
https://upload.wikimedia.org/wikipedia/commons/2/2b/Canada_Newfoundland_and_Labrador_Density_2016.png  
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 1.3 Research Objectives 
The purpose of this study is to evaluate clinical outcomes following coronary 
revascularization of multi-vessel disease patients at a medium volume cardiac catheterization 
centre through a retrolective cohort study design. Furthermore, this project seeks to assess 
clinical outcomes in low-risk triple vessel disease patients who have undergone complete 
revascularization to address an under-studied population in the literature. Therefore, the 
following research question is addressed upon the completion of this project:   
  
How does the management of LMCA disease in NL compare to the literature and are there 
significantly different mortality rates in low-risk triple vessel disease patients treated by complete 
revascularization via CABG or PCI from May 2006 to November 2015 in  
NL?  
 
Thus, the primary objective of this project is to provide one-year MACE statistics in 
isolated LMCA disease patients as well as mortality statistics, at varying levels of follow up, on 
low-risk triple vessel disease patients undergoing complete revascularization. Secondary 
objectives of this project are (a) assessing and comparing demographic and operative data from 
the NL patient cohort to larger clinical trials, (b) assessing long-term trends in post-operative 
mortality in low risk triple-vessel disease patients, and (c) assessing early and long term 
mortality in isolated LMCA disease patients undergoing treatment at the Health Science Centre, 
and (d) assessing the effect of conduit strategy on early and long term outcomes in CABG 
patients.  
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Chapter 2: Single centre experience of isolated left main disease management  
2.1 Abstract  
2.11 Background   
Coronary artery bypass graft (CABG) surgery has traditionally been the recommended 
revascularization strategy for isolated left main coronary artery (LMCA) disease. However, 
studies are emerging comparing PCI to CABG as a potential alternative in managing this 
population. The primary objectives of this study are to (a) evaluate single centre management of 
isolated LMCA disease through assessing freedom from Major Adverse Cerebrovascular and 
Cardiac Events (MACCE) at one year and (b) report on strategies and outcomes over a ten year 
period in comparison to the literature.  
  
2.12 Methods  
We performed a retrospective analysis using an institutional database of consecutive patients 
with isolated LMCA disease defined as an angiographically significant lesion ≥70%. Patients 
were excluded if they had an angiographically significant lesion in any additional coronary artery 
of >50%, or required cardiac surgery for another class I indication.     
  
2.13 Results  
115 patients with isolated LMCA disease were identified from May 2006 to October 2015. 
Ninety-nine patients were revascularized with CABG, seven with PCI, and nine treated 
medically, with an overall median follow up of 4.45 years. Five-year mortality rates were: 8.1% 
with CABG, 42.9% with PCI (high risk patients), and 0% with medical therapy patients. The rate 
of major adverse cardiac or cerebrovascular events at 1 year was 5.1% in the CABG cohort. 33% 
of CABG patients were revascularized with bilateral internal mammary artery and this strategy 
was associated with a non-significant trend towards improved five-year survival.  
  
2.14 Conclusions  
The majority of isolated LMCA disease patients in our centre continued to be treated with CABG 
with excellent short and mid-term results. Bilateral internal mammary arteries represented a 
common safe revascularization strategy.   
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2.2 Introduction  
Approximately 4% of all patients undergoing coronary angiography are diagnosed with 
left main coronary artery disease (LMCA) and of these <20% have isolated LMCA1.  
Historically, isolated LMCA has been treated exclusively with coronary artery bypass graft 
(CABG) surgery2. However, recent trials suggest a role for percutaneous coronary intervention 
(PCI) in patients with LMCA. The EXCEL3 trial indicated comparable long-term rates of major 
adverse cardiac or cerebrovascular events (MACCE) following revascularization with either 
CABG or PCI for LMCA, while the NOBLE4 trial reported a significantly higher long-term rate 
of MACCE associated with PCI.   
Given the restricted inclusion criteria for randomized controlled trials and the relative 
infrequency of isolated LMCA, it remains important to assess outcomes from prospectively 
collected databases to evaluate clinical practice in real-world populations. Additionally, clinical 
questions regarding optimal conduit selection for CABG, the need for quantitative assessment 
via intravascular ultrasound (IVUS) or Fractional Flow Reserve (FFR), and long term follow up 
remain understudied in the LMCA population. Despite observational trials showing improved 
survival with bilateral internal mammary arterial (BIMA) grafts, this conduit strategy remains 
underutilized in CABG patients5,6.  
The cardiac catheterization centre in St. John’s, NL offers a unique opportunity to 
evaluate and compare management of isolated LMCA in a small volume centre. Therefore, the 
primary objective of this study is to retrospectively evaluate management of isolated LMCA 
disease by describing treatment patterns and outcomes in comparison to current global practice. 
A secondary objective is to compare surgically treated patients with bilateral internal mammary 
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arterial (BIMA) grafts to single internal mammary arterial (SIMA) grafts.   
 
2.3 Methods  
2.31 Study Population  
  All consecutive patients treated for isolated LMCA disease in the province of 
Newfoundland & Labrador (NL) between May 1st, 2006 and October 31st, 2015 were screened 
for inclusion into this study. Patient data procurement and screening was accomplished utilizing 
the electronic Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease 
(APPROACH) database. The APPROACH database captured all patients who presented with 
clinical symptoms of coronary artery disease at the cardiac catheterization laboratory, located at 
the sole cardiac tertiary referral centre (The Health Science Centre, St. John’s) in the province. 
Therefore, all cardiac patients in the province of NL were captured by this prospectively 
collected database. The anonymous patient data was extracted with the following inclusion 
criterion: interventional cardiologist confirmed angiographically significant isolated LMCA 
disease, defined as left main stenosis greater than or equal to 70% with no other coronary artery 
stenosis of greater than 50% on coronary angiogram. Patients with indications for cardiac 
surgery other than coronary disease, such as concomitant valvular heart disease were excluded. 
All co-morbid variables included in analysis were based on information collected and stored in 
the APPROACH database. Co-morbid conditions were diagnosed and stored in APPROACH 
using standard diagnostic criteria. Variables were then extracted as “yes” or “no” data points 
during collection. Approval from the local human research ethics board and institutional review 
board (RPAC) was obtained prior to patient data extraction and analysis (HREB#2016.275).   
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2.32 Statistical Analysis  
  Categorical variables are presented as frequency and percentage. Continuous variables 
are presented as mean and standard deviation (SD). As there is no deliberate comparison of 
treatment modalities in this analysis, descriptive statistics compose the majority of the results. 
Cumulative survival of the CABG cohort was displayed on a Kaplan Meier curve. Hypothesis 
tests were evaluated using the alpha=0.05 level of significance (two-tailed). A regression 
analysis was completed with an entry level of p<0.05 and a stay level of p<0.20 for inclusion 
into the model. All statistical analyses were conducted using ©IBM SPSS 23 statistical software 
package.  
2.33 Outcomes  
  The objectives of this retrospective study were to evaluate the management of isolated 
LMCA disease at a single centre and report on outcomes and practice patterns over a ten-year 
period. Statistical comparison between the three treatment modalities, CABG, PCI, and medical 
management, was unable to be attained due to limitations in sample size of the population 
studied. Thus, the primary outcome was freedom from MACCE (defined as a composite of all-
cause mortality, non-fatal stroke, or repeat revascularization) at one year. The secondary 
outcome of this study was all-cause mortality post BIMA compared to all-cause mortality post 
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2.4 Results   
2.41 Patient Selection  
  A total of 26,697 patients were screened in the APPROACH database with the specified 
inclusion criteria in NL. Subsequently, 115 patients were identified as having isolated LMCA of 
>70% stenosis without any angiographically significant lesion in any other coronary artery of 
>50% from May 1st, 2006 to October 31st, 2015. Treatment modalities included CABG (n=99),  
PCI (n=7), and medical management (n=9). The patient selection process is shown in Figure 1. 
Approximately one quarter of the patients selected for this study were diabetic (n=27) and 14 
patients had a left ventricular ejection fraction (LVEF) of less than 50%. Furthermore, the 
majority of patients (n=88) in this study were classified as class 1 under the New York Heart 
Association (NYHA) classification system for heart failure. The remaining demographic data for 
each treatment modality are displayed in Table 1.   
  
 
Figure 1: Patient Selection. During the timeframe of this study, n=26,697 patients were identified to have received a 
cardiac catheterization at our centre. Of those patients, n=115 (0.4%) meet the criteria for isolated LMCA disease.  
Of the isolated LMCA disease patients, 86% received CABG, 6% received PCI, 8% received medical management.   
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	 reflecting	global	trends	and	changes	in	the	operator	experience.	  
  
Table 1	  
 CABG Cohort            PCI Cohort              Medical Cohort          
 (N=99) (N=7) (N=8) 
Age (years) 62.4 (9.98) 57.0 (10.91) 67.3 (13.07)* 
Male  67 (67.7%) 3 (42.9%) 7 (77.8%) 
Body-Mass Index (kg/m^2) 29.8 (4.99) 26.8 (3.14) 27.4 (3.06) 
Diabetes (T1 or T2) 22 (22.2%) 2 (28.6%) 3 (33.3%) 
Family History  58 (58.6%) 4 (57.1%) 6 (66.7%) 
Hyperlipidemia 87 (87.9%) 4 (57.1%) 8 (88.9%) 
Hypertension  70 (70.7%) 2 (28.6%) 5 (55.6%) 
Active Smokers  23 (23.2%) 3 (42.9%) 2 (22.2%) 
Previous Revascularization  
PCI 8 (8.1%) 0 1 (11.1%) 
CABG 0 0 0 
NYHA Class 
I 87 (87.9%)  1 (11.1%) 
II 4 (4.0%)  1 (11.1%) 
III 2 (2.0%)  0 
IV 2 (2.0%)  0 
Indication  
Stable Angina 6 (6.1%) 1 (14.3%) 5 (55.6%) 
Unstable Angina 19 (19.2%) / / 
Acute Coronary Syndrome 0 6 (85.7%) 1 (11.1%) 
Renal Insufficiency 3 (3.0%) 0 1 (11.1%) 
Peripheral Vascular Disease  4 (4.0%) 1 (14.3%) 1 (11.1%) 
Pulmonary Disease  18 (18.2%) 1 (14.3%) 0 
Obesity (BMI>30.0kg/m^2) 41 (41.4%) 0 2 (22.2%) 
Liver Disease  1 (1.0%) 0 0 
Cerebrovascular event  12 (12.1%) 1 (14.3%) 0 
LVEF <50% 10 (10.1%) 3 (42.9%) 1 (11.1%) 
Table 1. Demographic characteristics of each treatment group. Continuous variables are presented as mean (standard deviation) and categorical 
variables are presented as frequency (percentage). LVEF = Left Ventricular Ejection Fraction; NYHA = New York Heart Association. *Average age 
at time of catheterization .  
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2.42 Procedural Details  
  The distribution of isolated LMCA patients treated with either CABG or PCI per year is 
shown in Figure 2. As expected, the majority of patients in this population are treated with 
CABG (n=99), with a small proportion treated with PCI (n=7) and medically (n=9). Of the 
patients treated surgically, there were an average 2.26 grafts per patient with 94.9% of patients 
having an internal mammary artery graft. Furthermore, 79.8% of the surgically managed patients 
were treated via cardiopulmonary bypass machine. Approximately one third of surgical patients 
received bilateral internal mammary artery grafts (n=33). Further operative details for the CABG 
cohort are presented in Table 2. The median length of time from catheter angiogram to operation 
was 6 days with no mortality prior to surgery.   
2.43 Composite MACCE  
  The rates of composite MACCE at 30 days and 1 year for the CABG cohort were 2.0% 
and 5.1%, respectively. The rates of composite MACCE at 30 days and 1 year for the PCI cohort 
were 28.6% and 57.1 %, respectively. Composite MACCE rates for surgical and PCI patients are 
shown in Table 3. The survival curve for 1-year MACCE in the CABG cohort is presented in 












Table 2	  
 CABG Cohort N=99 
On Pump  79 (79.8%) 
Total Number of Grafts  224 
Average Grafts per Person 2.26 (0.06) 
Patients with > 2 Grafts 30 (30.3%) 
No. of Patients with Arterial Grafts 94 (94.9%) 
Patients with an Internal Mammary Graft 94 (94.9%) 
No. of Patients with BIMA Grafts 33 (33.3%) 
No. of Patients with SIMA Plus Vein Grafts 54 (54.5%) 
No. of Patients <65 Years Old with  
33/37 (89.4%) 
Arterial Grafts 
No. of Patients >65 Years Old with  
61/62 (98.4%) 
Arterial Grafts 
No. of Patients with an IABP 7 (7.1%) 
Table 2: Operative details for CABG cohort. BIMA = Bilateral Internal 
Mammary Artery; IABP = Intra Aortic Balloon Pump; SIMA = Single Internal 
Mammary Artery.  






2.44 All-cause Mortality and Repeat Revascularization  
  A total of 11 deaths occurred with a median follow up of 4.45 years (range 0.03 to 9.59 
years), with n=8 (8.1%) in the CABG cohort and n=3 (42.9%) in the PCI cohort (Table 3). 
Survival at 30 days, 1 year, and 5 years in the CABG cohort was 99.0%, 96.0%, and 91.9%, 
respectively. Five of the seven PCI patients (71.4%) survived to 30 days and 4 (57.1%) survived 
for the duration of the study period. There were two repeat revascularizations throughout the 
study period, with n=1 (1.0%) in the CABG cohort and n=1 (14.3%) in the PCI cohort (Table 3). 
Overall Kaplan-Meier survival at 5 years in the CABG cohort is shown in Figure 4.  
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2.45 Comparison of Bilateral Mammary Artery Usage to Single Mammary with Saphenous Vein  
   In the CABG cohort, 33 patients (33%) received BIMA, 54 patients (55%) received a  
SIMA and a vein and 12 patients (12%) received other graft strategies. In patients younger than 
65, 46.8% (n=29) received BIMA grafts as a conduit strategy, while 40.3% (n=25) of patients 
received SIMA grafts as a conduit strategy. The 5-year survival rates in the BIMA and SIMA 
groups are 93.9% and 88.9%, respectively. Figure 5 shows the Kaplan-Meier survival of BIMA 
grafted patients versus SIMA grafted patients. At 1, 3, and 5-year follow up there is no 
significant difference in survival between each subgroup (p=0.838, p=0.987, p=0.459, 
respectively).   
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2.46 Regression Analysis  
  To predict mortality for the CABG cohort, variables including LVEF<50%, hypertension, 
hyperlipidemia, prior PCI, age at procedure, urgency of procedure (emergent vs urgent vs 
elective), angina status, BIMA versus SIMA grafts, Type 1 Diabetes, and Type 2 Diabetes, were 
included into the regression model. Of the included variables, LVEF<50% and Type 2 Diabetes 
were the only significant predictors of mortality at 5 years (p=0.003, p=0.008, respectively).   
  
2.5 Discussion  
  Results of this single centre experience of revascularization for isolated LMCA show that 
a high proportion of patients continue to be treated with CABG. This result was to be expected, 
given the historical context of CABG in isolated LMCA management. The results indicate that 
CABG surgery is associated with excellent short and medium-term survival and freedom from 
MACCE. The results from this study also indicate an 8.1% 5-year mortality rate associated with 
isolated LMCA patients who are treated with a surgical modality.   
It is notable that the 5-year mortality rate in the CABG cohort (8.1%) is comparable to 
5year mortality rates in other studies (14.6% in SYNTAX7, 7.9% in PRECOMBAT8, and 9% in 
NOBLE4). Moreover, in the CABG cohort, only Type 2 diabetes and a reduced ejection fraction 
were significant predictors of mortality. In the PCI cohort, the 5-year mortality rate (42.9%) was 
much higher than reported in larger trials (12.8% in SYNTAX7, 5.7% in PRECOMBAT8, and 
12% in NOBLE4). However, only seven patients were treated with PCI in this study, giving a 
sample size that is too small to draw any significant conclusions. Of the seven patients who were 
treated with PCI, five were deemed unstable and the remaining two had ostial lesions that were 
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stented in accordance with the 2014 ACC guidelines9. The unstable patients were declined for 
surgery and went for salvage PCI because of ongoing hemodynamic instability. This suggests 
that PCI in our centre was used more often in patients who were in an emergency state and likely 
accounts for the increased primary outcome.   
In total nine patients were treated with medical management despite having an 
angiographic lesion between 50 and 60%. All of these patients remained alive at five-year follow 
up. On further evaluation, none of these patients had presented with acute coronary syndrome 
and five patients were asymptomatic with normal exercise stress tests. The additional four 
patients who remained on medical therapy underwent FFR or IVUS and did not have significant 
flow limiting lesions. This result suggests the importance of both patient symptoms and 
quantitative measurements of lesion severity over purely angiographic appearance.   
The rate of MACCE one-year post CABG, as per our definition, is 5.1% and this is 
comparable to the one-year data from PRECOMBAT8 (5.7%). The CABG cohort has a 5-year 
repeat revascularization rate lower than that seen in randomized trials (1% vs 15.5% in  
SYNTAX7, 21% in PRECOMBAT8, and 10% in NOBLE4). Our cohort is younger than the 
cohort in SYNTAX7 and NOBLE4 and less likely to be diabetic than the patients in  
PRECOMBAT8. As well, the patients in previous studies were more likely to have concomitant 
multivessel disease4,7,8. Finally, our lower rates of repeat revascularization may be partly due to 
our more frequent use of arterial grafts.  
Within the CABG cohort, the surgical strategy consisted of at least a single mammary in  
94.9% of patients and bilateral mammary grafts in 33% of patients. This is even more 
pronounced in patients under 65 years of age where 46.8% received BIMA grafting. The ability 
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to perform BIMA grafting in one-third of patients in this study demonstrates how this strategy 
can be used in urgent situations. The rate of BIMA usage in this study is significantly higher than 
that reported in the STS database (33% vs. 4.1%)10. The BIMA group demonstrates a 
nonsignificant trend towards a lower 5-year mortality rate (93.9% compared to 88.9%), which is 
comparable with results seen in other observational trials5. Despite the potential survival benefit 
demonstrated with BIMA, there has been no increase in the use of BIMA grafting with CABG6.  
Longer follow up is likely needed before a statically significant survival benefit is seen with 
BIMA revascularization in isolated LMCA; however, the results from this study suggest a 
potentially beneficial result and this strategy remains the preferred technique at our centre.  
Prior to 2014 there was only a single case of PCI for isolated LMCA performed in NL, 
however with resulting changes in guidelines9, six PCI procedures were done between 2014 and 
2016. The use of PCI may be underutilized at our centre and the reasons for this are likely 
multifactorial. Our study only extends to October 2015 and the guidelines only support PCI as an 
alternative to CABG as of 2014. Further follow up data is likely needed before adequate 
conclusions can be drawn regarding PCI use at our centre.   
  This study has several limitations. The retrospective, non-randomized study design may 
result in selection bias. Five of the seven patients in the PCI cohort were too unstable and 
declined for surgical revascularization and thus underwent PCI. Therefore, a direct comparison 
of different treatment modalities for isolated LMCA was not possible due to the differences in 
prognostic variables and indications for long term complications. Furthermore, the recent 
guideline change in the literature may ultimately result in a change in practice that will not be 
evident through this study population. Despite the limitations of this study, single centre 
evaluation of isolated LMCA disease treatment remains an effective method of assessing local 
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practice with respect to global trends. The results from this study provide confidence that CABG 
is safe for isolated left main disease and that revascularization can be achieved with high rates of 
bilateral internal mammary usage.   
  
 2.6 Conclusion    
The results from this study provide confidence that CABG is safe for isolated left main 
disease and that revascularization can be achieved with high rates of bilateral internal mammary 
usage.  CABG represented the most common form of revascularization for isolated left main 
coronary disease in this single centre with excellent short and mid-term morbidity and mortality.  
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3.1 Abstract   
3.11 Background  
Multivessel coronary artery disease (MVD) predisposes patients to increased risk of cardiovascular 
morbidity and mortality. Current guidelines from the Canadian Cardiovascular Society (CCS) outline 
evidence for Coronary Artery Bypass Grafting (CABG) in high anatomically complex coronary lesions. 
However, in low and intermediate anatomically complex coronary disease, percutaneous coronary 
intervention (PCI) has demonstrated non-inferior outcomes.   
  
3.12 Methods/Results  
This study captures all patients who were treated for triple-vessel disease via PCI or CABG in the 
province of Newfoundland & Labrador between 2006 and 2015. Patients were screened for >70% stenosis 
in three major cardiac territories (Right Coronary, Left Anterior Descending, & Left Circumflex), not 
including the left main coronary artery. Included patients were required to have been completely 
revascularized in each territory for both CABG and PCI. Complex anatomical lesions, including left main 
disease, proximal lesions, lesions at bifurcations, diffuse disease, and completely occluded vessels were 
excluded. A total of 1604 patients were extracted from the Alberta Provincial Project for Outcome 
Assessment in Coronary Heart disease (APPROACH) database, with 45 patients in the PCI cohort and 
1559 patients in the CABG cohort (median follow up = 5.4 years). The primary outcome of in-hospital 
mortality rates was 2.2% and 1.2% in the PCI and CABG cohorts, respectively (p=0.533). A matched 
comparison was completed using a propensity score model. After matching 36 patients in the PCI cohort 
to 36 patients in the CABG cohort, the in-hospital mortality rates were 0% and 2.8%, respectively 
(p=0.317). Finally, a secondary outcome of 5 year mortality rates within the CABG cohort based on graft 
strategy was assessed. 5-year mortality rates were 5.4% for the 296 patients treated with bilateral internal 
mammary artery grafts and 15.2% for the 564 patients treated with single internal mammary artery grafts.  
  
3.13 Conclusion   
Early survival rates are comparable in low-risk triple-vessel disease patients revascularized with either 
therapy. A secondary outcome of this study shows that the graft strategy of using bilateral internal 
mammary artery compared to a single internal thoracic artery appears to have a medium-term survival 
benefit; however, further investigation is warranted to evaluate this group as a primary outcome.   
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3.2 Introduction  
Multi-vessel coronary artery disease (MVD) predisposes patients to an increased risk of 
cardiovascular morbidity and mortality. Therapeutic interventions for MVD include optimal 
medical management, percutaneous coronary intervention (PCI), and coronary artery bypass 
grafting (CABG). CABG was introduced as a coronary revascularization technique in 19671 and 
initial clinical trials demonstrated a long-term survival advantage associated with surgery among 
patients with reduced ejection fraction, more complex disease, and diabetes, when compared to 
conventional medical management2,3. However, the development of PCI in 19784 prompted the 
need for more conclusive evidence regarding the long-term outcomes following each respective 
coronary revascularization. Initial randomized controlled trials (RCTs) compared balloon  
angioplasty to conventional CABG surgery; however, no definitive conclusions were drawn5-10.  
Modern advancements in PCI, namely bare-metal and drug-eluting stents, motivated several 
RCTs directly comparing PCI to CABG11-15. However, the results from these trials are 
conflicting and loss to follow-up is a limitation11-15. Although CABG may have a long-term 
survival advantage, PCI presents a potential safe cost-saving alternative thus warranting further 
comparative evaluation16.  
There have been extensive studies published on comparative outcomes between PCI and 
CABG patients, but there has been little comparative outcome evidence in completely 
revascularized patients with low anatomical complexity. The SYNTAX trial reports a non-
significant difference in all-cause mortality between completely revascularized and incompletely 
vascularized triple-vessel disease patients17; however, a direct comparison between completely 
revascularized CABG and PCI patients was not included. Furthermore, although the results from 
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large RCTs have a significant impact on guideline establishment for MVD, the use of a real-
world registries is critical in validating the conclusions of controlled trials in clinical settings. 
Therefore, the primary objective of this study is to retrospectively compare triple-vessel 
disease patients with low to intermediate coronary complexity who underwent complete 
revascularization with either PCI or CABG over a nine-year period at the sole, tertiary cardiac 
care centre responsible for providing advanced cardiac care for the entire population of 
Newfoundland and Labrador (NL), the furthest east Canadian province.  Within the context of 
CABG revascularization, bilateral mammary artery grafting represents a common conduit 
strategy used at our centre. Thus, secondary objectives include determining significant predictors 
of early and late mortality and determining the effect of conduit strategy (including BIMA) on 
mortality in surgical patients.   
  
3.3 Patients and Methods  
3.31 Patient Population  
All patients treated for triple-vessel coronary artery disease in NL between May 1st, 2006 
and October 31st, 2015 were screened for inclusion into this retrospective study. De-identified 
patient data were extracted with the following inclusion criteria: confirmed ≥70% stenosis in all 
three major coronary artery systems and complete functional revascularization in each affected 
territory with either CABG or PCI. Complete functional revascularization was defined as an 
intervention (via stent or graft) in all affected territories. All patients included in this study were 
reviewed at a multidisciplinary team rounds post initial coronary angiogram. In discussion with 
Cardiac Surgeons and Interventional Cardiologists, it was deemed that the patients’ coronary 
anatomy was considered of sufficiently “low anatomical complexity” with focal lesions in a 
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coronary artery of each major territory that could be treated via either CABG or PCI. The final 
decision for revascularization therapy was determined based on several factors including patient 
preference, patient comorbidities, symptom characteristics, and timing of presentation. Patients 
with valvular heart disease, critical left main coronary artery disease, proximal lesions, lesions at 
bifurcations, diffuse disease, and completely occluded vessels and/or incomplete functional re-
vascularization were excluded from this cohort. While Syntax score information was not 
available for patients in this database, the patients were assumed to be equivalent to low-syntax 
scores due to the exclusion criteria. Patients with complex disease patterns and/or prognostic 
factors that would make them poor surgical candidates were not included in this study. Local 
multidisciplinary rounds occur weekly and include discussion about a given patient’s indication 
for either PCI or CABG. Patient’s included in this study were presumed to be eligible for both 
interventions based on definite indications, clinician discussion, and patient preference. Patients 
excluded from this study are presumed to be of higher Syntax scores, based on the exclusion 
criteria, and thus in a high-risk category.  
  
3.32 Study Design  
In this single-centre retrospective cohort analysis, all patients who met the criteria for this 
study were analyzed and compared. Data from the prospectively collected Alberta Provincial 
Project for Outcome Assessment in Coronary Heart Disease (APPROACH) database, which has 
been active in NL since 2006, allowed for the opportunity to assess long-term complications and 
outcomes of each respective intervention, including a complete follow up. APPROACH contains 
clinical information that is collected by trained professionals through the cardiac catheterization 
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laboratory. Thus, the database captured all patients who presented with clinical symptoms at the 
cardiac catheterization laboratory, located at the sole tertiary referral centre in the province, due 
to local practice requiring a catheterization procedure prior to any revascularization operation.  
Approval from the local human research ethics board (HREB) and institutional review board 
(RPAC) was obtained prior to patient data extraction and analysis (HREB #2016.347).    The 
primary outcome of this study was in-hospital mortality in the CABG and PCI cohorts, 
respectively. Secondary outcomes included unmatched and matched short to long term mortality 
in CABG and PCI cohorts, mortality based on graft utilization, significant predictors of 
mortality, and descriptive statistics on the study population. All outcome data were available in 
the APPROACH database and were extracted using keyword searches. APPROACH captures 
post-operative details in hospital up to thirty days with long-term mortality rates beyond 30 days 
obtained via a provincial health database.  The provincial database is robust and contains health 
records of all patients in the province, including long-term mortality. Significant predictors of 
mortality were assessed at 30 days, 1 year, 3 years, and 5 years in the overall patient cohort as 
well as the unmatched CABG cohort and PCI cohort separately.   
  
3.33 Statistical Analysis  
Categorical variables were presented as frequency and percentage. Continuous variables 
were presented as a mean and standard deviation (SD). Categorical variables and continuous 
variables were compared using a chi-squared test and a student’s t test, respectively. Patients in 
the CABG population were matched to patients in the PCI population in a 1:1 ratio via 
propensity score weighting based on the following variables: sex, age, type 2 diabetes, ejection 
fraction < 50% and renal insufficiency. These variables were determined via clinical judgement. 
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A match tolerance level of 0.05 was used to match variables in the propensity score model. 
Cumulative survival was assessed in the matched and unmatched population using the Kaplan-
Meier method with factors compared via the log-rank test. Cox regression analysis was used to 
identify any significant predictors of outcome variables in the overall cohort as well as several of 
the subgroups. An entry level of p<0.05 and a stay level of p<0.10 was used for all independent 
covariates entered into the model. Hypothesis tests were evaluated using the alpha=0.05 level of 
significance (two-tailed), with p<0.05 considered to be significant. All statistical analyses were 
done using the ©IBM SPSS 23 statistical software package.   
  
3.4 Results  
3.41 Subjects   
Of the 26,697 patients screened, 6.0% (n=1,604) of patients met the inclusion criteria for 
this study, with 1559 in the CABG cohort and 45 in the PCI cohort (Figure 1). The CABG cohort 
had a significantly higher number of moderate urgency cases (p<0.001). The PCI cohort had a 
significantly higher number of extreme cases (i.e. either elective or emergent; p<0.001 and 
p=0.007 respectively). Furthermore, the PCI cohort had a significantly higher number of cases 
with previous coronary revascularization history through stent placement. The baseline 
demographic characteristics of the unmatched study population at baseline are shown in Table 1. 
Following the propensity score match model, 36 matched cases remained in each cohort. The 
majority of baseline characteristics did not differ between the two cohorts following the match.  
However, there were a higher number of cases with previous coronary revascularization history 
through stent placement in the PCI cohort. Baseline demographic characteristics of the matched 
population are shown in Table 2. Operative details and statistics are shown in Table 3.     
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Figure 1: Patient selection. Total cardiac catheterizations reflect the total number of patients assessed at the cardiac 
cath lab from May 2006 to October 2015. From these patients, 6% of patients met the inclusion criteria for this 
particular study. Morover, 97% of patients in this study were revascularized with CABG, while 3% were 
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Table 1  
  
 CABG        PCI              
Significance 
 (n=1559) (n=45) 
Age  64.01 (9.0) 63.26 (11.5)  NS 
Male  1007 (81%) 36 (80%) NS 
BMI  29.68 30.17 NS 
Obesity  658 (42%) 23 (51%) NS 
Current Smokers 403 (26%) 9 (20%) NS 
Priority 
Emergency 24 (1.5%) 4 (8.9%) p=0.007 
Urgent  1437 (92.2%) 31 (68.9%) p<0.001 
Emergency Salvage  1 (0.1%) 1 (2.2%) p=0.0550 
Elective (Low Risk)  97 (6.2%) 9 (20%) p<0.001 
Previous Revascularization 
PCI  140 (9%) 10 (22%) p=0.003 
CABG 0 0 / 
Type 2 Diabetes 516 (33%) 16 (36%) NS 
Family History 1002 (64%) 27 (60%) NS 
Hypertension  1176 (76%) 31 (69%) NS 
Heart Failure  83 (5%) 2 (4%) NS 
Renal Insufficiency  103 (7%) 2 (4%) NS 
Peripheral Vascular Disease 123 (8%) 2 (4%) NS 
Cerebrovascular Disease  128 (8%) 4 (9%) NS 
Pulmonary Disease 270 (17%) 7 (15.6%) NS 
Liver Disease 6 (0.4%) 0 NS 
LVEF < 50% 443 (28%) 16 (36%) NS 
Table 1. Demographic characteristics of each treatment group in the unmatched population. Continuous variables are presented as mean (standard 
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Table 2  
  
 CABG            PCI              
Significance 
 (n=36) (n=36) 
Age  64.53 62.69 NS 
Male  32 29 NS 
BMI  29.63 29.7 NS 
Obesity  15 19 NS 
Current Smokers 10 7 NS 
Priority 
Emergency 1 2 NS 
Urgent  31 26 NS 
Emergency Salvage  0 0 NS 
Elective (Low Risk)  4 8 NS 
Previous Revascularization 
PCI  18 9 p=0.029 
CABG 0 0 NS 
Family History 24 21 NS 
Type 2 Diabetes 14 14 NS 
Hypertension  29 27 NS 
Heart Failure  3 2 NS 
Renal Insufficiency  3 2 NS 
Peripheral Vascular Disease 12 2 NS 
Cerebrovascular Disease  5 4 NS 
Pulmonary Disease 5 5 NS 
Liver Disease 0 0 NS 
LVEF < 50% 15 14 NS 
Table 2. Demographic characteristics of each treatment group in the unmatched population. Continuous variables are presented as mean 




3.42 Mortality  
There was a total mortality rate of 9.5% (n=153) during the study timeline in the total 
patient population. The primary outcome of in-hospital morality rates was 1.2% (n=19) and 2.2% 
(n=2) in the unmatched CABG cohort and PCI cohort, respectively (p=0.533). The in-hospital 
mortality rates for the CABG cohort and PCI cohorts in the matched analysis were 0% and 2.8%, 
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respectively (p=0.317). The 1-year mortality rates for the CABG and PCI cohort in the matched 
analysis were 2.7% (n=1 of 34) and 9.7% (n=3 of 31), respectively (p=0.266). The 3-year 
mortality rates for the CABG and PCI cohort in the matched analysis were 6.9% (n=2 of 29) and 
16.7% (n=3 of 18), respectively (p=0.283). Finally, the 5-year mortality rates for the CABG and  
PCI cohort in the matched analysis were 12.0% (n=3 of 25) and 37.5% (n=3 of 8), respectively 
(0.075). The mortality rates of both cohorts in the unmatched and matched comparison are 
shown in Table 4. Of the 1,604 patients enrolled in this study, 90.5% (n=1,451) survived until 
censorship with a median follow up of 5.4 years. Kaplan-Meier survival curves comparing 
CABG and PCI survival for the unmatched population are shown in Figure 2, while the survival 
curves for the matched population are shown in Figure 3.   
 
3.43 Cox Regression Analysis  
In the overall population, poor ejection fraction (<50%) was a significant predictor of 
mortality at all stages of follow up (p=0.046, p=0.008, p<0.001, and p<0.001 respectively).  
Renal insufficiency, defined as presence of CKD or an event that requirement medical 
management and/or dialysis, was a significant predictor at 1 year, 3 years, and 5 years post 
intervention (p=0.001, p<0.001, and p<0.001, respectively). Finally, age and year of procedure 
were significant predictors of mortality at 3 years (p=0.030 and p=0.011, respectively) and 5 
years (p=0.004 and p<0.001, respectively). Within the CABG and PCI cohort stratifications, 
there were no significant predictors of mortality at any length of follow up in the PCI cohort. In 
the CABG cohort, there were no predictors at 30 days; however, age, poor ejection fraction, and 
renal insufficiency were significant predictors of mortality at 1 year (p=0.003, p=0.001, and 
p<0.001 respectively) and at 3 years (p=0.006, p<0.001, and p<0.001 respectively) whilst at 5 
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years the significant predictors of mortality were age, year of procedure, poor ejection fraction, 
and renal insufficiency (p=0.001, p<0.001, p<0.001, and p<0.001 respectively).   
 
Table 3  
  
 PCI (n=45) CABG (n=1559) 
Stent Type Off-pump 135 (9%) 
BMS 9 (20%) Average Pump Time*  119.8 
DES 42 (93%) Thoracic Artery Usage 1512 (97%) 
Balloon 43 (96%) Bilateral Artery Usage 440 (28%) 
Access Site  IABP 45 (3%) 
Left Femoral 6 (13%) Complications 782 (50%) 
Left Radial 1 (2%) Returned to OR  69 (4%) 
Right Femoral 21 (47%) Cardiac Complications 5 (0.3%) 
Right Radial 17 (38%) Infection 138 (9%) 
Second Access Site (PCI) 5 (11%) Neuro Complication 198 (13%) 
Average Size 2.7 (0.36) Renal Complication 149 (10%) 
Average Length 14.4 (2.9) Vascular Complication 14 (0.9%) 
Average Pressure 15.9 (3.6)  Cardiac Arrest  28 (2%) 
Average Duration  19.6 (8.9) Perioperative MI 5 (0.3%) 
Total Stents 441 Cardiac Tamponade 3 (0.2%) 
No. BMS 38 (9%) Atrial Fibrillation 437 (28%) 
No. DES 202 (46%) New Q wave 2 (0.1%) 
No. Aspiration Catheters 3 (0.6%) GI Complications 54 (4%) 
No. Balloon 198 (45%) Renal Insufficiency  121 (8%) 
Average Stents 9.8 (5.5) 
Table 3: Operative details and complications. BMS = Bare metal stent; DES = Drug eluting stent; IABP 
= Intra-aortic balloon pumpl; MI = Myocardial infarction; GI = gastrointestinal complications. *Average 
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Table	 4	  
  
 UNMATCHED POPULATION MATCHED POPULATION 
 CABG PCI CABG PCI 
30 Days 19/1559 (1.2%) 2/45 (2.2%) 0 1 (2.8%) 
1 Year 38/1409 (2.7%) 3/35 (8.6%) 1/34 (2.9%) 3/31 (9.7%) 
3 Years 73/1138 (6.4%) 3/21 (14.3%) 2/29 (6.9%) 3/18 (16.7%) 
5 Years 112/890 (12.6%) 3/10 (30%) 3/25 (12.0%) 3/8 (37.5%) 
Table 4: Mortality data for the unmatched and matched populations. Follow up is measures from the time of procedure. The fraction of 
people represent the patients with each respective level of follow up.  
  
Figure	2:	Survival	in	unmatched	patient	cohort.	Kaplan-Meier	Survival	curves	 for	follow	up	at	30	days,	1	year,	3	years,
	 and	5	years.	Median	level	of	follow	up	was	5.4	years	in	the		study	population.  
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3.44 Conduit Strategy Stratification   
A total of 1,512 patients (97%) received an internal mammary artery graft, 440 (29%) of 
which were bilateral internal mammary grafts. Furthermore, 47 patients had either missing graft 
utilization data or were treated with no internal mammary artery graft. Operative details for the  
CABG cohort are presented in Table 3. Comparison of the patients with Bilateral Internal  
Mammary Grafts (BIMA) versus patients with a Single Internal Mammary Graft (SIMA) 
revealed a significantly younger population in the BIMA group (average age = 59.6 vs 65.8, 
respectively; p<0.001). Moreover, the SIMA group had a significantly higher proportion of 
patients with Type 2 Diabetes (p<0.001), renal insufficiency (p=0.001), and poor LVEF  
(p<0.001). Mortality rates in the BIMA group at 30 days, 1 year, 3 years, and 5 years were 0.5%, 
0.7%, 2.2%, and 5.4% respectively. Mortality rates in the SIMA group at 30 days, 1 year, 3 
years, and 5 years were 1.4%, 3.1%, 7.8%, 15.2% respectively.   




	 on	5	prognostic	factors,	yielding	n=36	 patients	 in	each	matched	cohort.		Kaplan-Meier	Survival	curves	for	follow	up
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 3.5 Discussion 
Although many studies have evaluated outcomes in coronary revascularization5-15, this 
study presents short and long-term outcomes following complete coronary revascularization in 
triple-vessel disease patients with low anatomical complexity. In this population, prior to 
revascularization it was felt by cardiac surgeons and interventional cardiologists that PCI and 
CABG would both provide full revascularization with equivalent mortality outcomes. The data 
collected over a retrospective nine-year period indicated that surgical revascularization is the 
dominant intervention chosen for triple-vessel presentation in NL. However, recent years have 
showcased an increasing number of triple-vessel PCI cases. Firstly, the results of this study show 
that there were no significant differences in short- or long-term mortality between the CABG and  
PCI cohorts, after accounting for important prognostic variables with a propensity score. 
Secondly, there are increasing numbers of PCI cases at our medium volume centre for patients 
with triple-vessel disease. Thirdly, poor ejection fraction, renal insufficiency, and age at time of 
procedure were significant predictors of long-term mortality. Finally, there is a suggestive trend 
towards a long-term survival advantage in CABG patients that were treated with bilateral 
mammary artery grafts as opposed to a single internal mammary graft that warrants further 
investigation.    
Our results are consistent with several large randomized controlled trials, including the 
clinical SYNTAX, MASS II, and ERACI II Trials. The SYNTAX trial included patients with 
three vessel disease and/or Left Main Coronary Artery Disease demonstrated significantly higher 
rates of Major Adverse Cardiac or Cerebrovascular Events (MACCE) in the PCI cohort when 
compared to the CABG cohort. In comparison to our results, the SYNTAX trial had comparable 
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rates of mortality in the CABG cohort (3.5% vs 2.7%), but lower rates of mortality in the PCI 
cohort (4.4% vs 8.6%) at one year19. At long-term follow up, comparable rates in the CABG 
cohort remained consistent (11.4% vs 12.6%) and mortality rates in the PCI cohort were 
significantly lower (13.9% vs 30%)20. The ERACI II trial concluded there was no significant 
difference in survival in multivessel disease patients treated with either PCI or CABG 
revascularization strategies. Initial outcome data from the ERACI II trial revealed a higher 
mortality rate in the CABG cohort compared to our results (5.7% vs 1.2%) and lower mortality 
rate in the PCI cohort compared to our results (0.9% vs 2.2%)21. A long-term follow up of the 
ERACI study cohort at 5 years showed a similar mortality rate in CABG patients compared to 
our results (11.5% vs 12.6%) and a significantly lower mortality rate in the PCI cohort compared 
to our results (7.1% vs 30%)22. Finally, the MASS II randomized multi-vessel disease patients to 
either CABG, PCI, or medical management and determined that there was no significant 
difference in all-cause mortality between any treatment modality. At 5 years of follow up, the  
MASS II trial had a similar mortality rate in the CABG cohort compared to our results (12.8% vs 
12.6%) and a significantly lower mortality rate in the PCI cohort compared to our results (15.5% 
vs 30%)13.   
  The population assessed in this study were discussed at multidisciplinary rounds and are 
assumed to be of low SYNTAX score. Exclusion criteria for this study were designed to avoid 
patients with the higher disease complexities that are seen in typical high SYNTAX score 
patients. Studies have examined comparative outcomes in low-syntax score patients and the 
SYNTAX trial demonstrated that CABG shows improved outcomes over PCI in patients with 
intermediate/high SYNTAX scores, while there is no significant survival advantage to either 
revascularization modality in patients with low syntax scores. Head et al. completed a report on 
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the three-vessel disease population of the SYNTAX Trial18 and evaluated outcomes in low 
syntax score patients. The 5-year mortality rate in their population was 9.3% in the CABG cohort 
and 10.2% in the PCI cohort, with no significant difference in all-cause mortality20. Our results 
had a higher mortality rate in both cohorts (12.6% and 30%, respectively).  
Several studies emphasize the importance of complete revascularization in patients 
undergoing therapeutic revascularization via PCI and CABG17,18. Garcia et al. meta-analyzed 
data from 35 RCTs including approximately ninety thousand patients who were separated into 
those who were completely revascularized versus incompletely revascularized and a 30% 
reduction in overall mortality was shown with complete revascularization versus incomplete 
revascularization17. Complete revascularization in their study was achieved more commonly in 
the CABG group versus the PCI group; however, a significantly higher mortality rate was shown 
in the incompletely revascularized patients in both the CABG and PCI groups (RR: 0.70, 
p<0.001 and RR: 0.72, p<0.001, respectively). Head et al. examined subgroup data from the 
SYNTAX trial and also observed a higher rate of incomplete revascularization in the PCI cohort 
compared to the CABG cohort (43.3% versus 36.8%)18. However, in this study there was 
evidence of a higher rate of MACCE associated with the incompletely revascularized PCI 
patients (76.2% versus 66.5%, p<0.001), but no such evidence was found in the CABG cohort18. 
Furthermore, when mortality was assessed independently as a secondary outcome, no evidence 
was found in favor of complete revascularization.   
This study has several limitations. Firstly, the propensity score model cannot account for 
all selection bias in the treatment modality. At this local centre, ambiguous patients are presented 
at multi-disciplinary rounds for consultation on a treatment modality. Thus, there are a multitude 
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of factors that are discussed at rounds and not all of those can be accounted for through the 
propensity score match model, including patient preference. This is certainly a limitation because 
there is no data collected on an objective measure, such as the SYNTAX score, that would 
determine these patients to be low risk.  Secondly, although the APPROACH database is an 
excellent resource for collecting local outcome data, many of the variables from the earlier stages 
of the active database contained missing values and therefore could not be assessed properly. 
Thirdly, the regression analysis is significantly limited with regards to the overall population 
because it is driven by the CABG cohort. Finally, this study timeline encompasses many 
technological and procedural advancements in both CABG and PCI operations that may bias the 
outcomes assessed in this study. Further evaluation is warranted to account for the increasing 
PCI triple-vessel disease cases in recent years to fully understand the comparative efficacy 
relative to CABG therapy.    
  
3.6 Conclusion  
Early survival rates are comparable in low-risk triple-vessel disease patients 
revascularized with either therapy. A secondary outcome of this study shows that the graft 
strategy of using bilateral internal mammary artery compared to a single internal thoracic artery 
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 Chapter 4: Summary & Synthesis  
 4.1 Summary 
Coronary artery disease continues to have significant demand on the modern healthcare 
system as our population ages. According to data from the Canadian Institute for Health  
Information, Acute Myocardial Infarction (AMI), a common and potentially lethal progression of  
CAD, is the third most common cause for inpatient hospitalization behind Chronic Obstructive  
Pulmonary Disease (COPD) exacerbation and childbirth (Canadian Institute for Health 
Information, 2019). One of the main goals of this project was to evaluate outcomes related to 
secondary prevention following confirmed CAD. The study design was created accordingly to 
offer primary literature on the efficacy of our current management and to potentially contribute 
to limiting the number of inpatient hospitalizations due to complications from CAD. Reducing 
the risk of an AMI would presumably improve quality of life of people affected by CAD. 
Although the published literature is vast on this CAD secondary prevention strategies, this study 
offers outcomes of our local management practices and how they compare with larger centres 
across the world.   
There are many strategies to approaching management of patients with CAD, including 
that of coronary revascularization, which has been discussed at length. The decision of how to 
optimally manage a patient with CAD is multifactorial and depends on anatomical complexity of 
the lesion, patient comorbidities, clinical severity of the disease, and patient preference. This 
project evaluates two different manifestations of CAD and outlines how each are specifically 
managed at a medium-volume cardiac centre in Newfoundland & Labrador, Canada.   
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In the first study, isolated LMCA patients are evaluated and compared to larger centres. 
Historically, CABG tends to be the dominant treatment modality in this population, which is 
reflected in our local practice as well. However, recent years have shown a slight increase in the 
number of isolated LMCA cases that are being managed percutaneously. The second study offers 
a detailed comparison of complete revascularization, through either PCI or CABG, in patients 
that are of a low-risk category of three-vessel disease. Similar to the first study, CABG tends to 
be the most common approach to these patients; however, multivessel PCI is becoming a more 
common option in our local practice with good outcomes. This also reflects global practice 
where the operator experience with percutaneous stenting continues to evolve. Although isolated 
LMCA disease and MVD are two separate entities of CAD with differing guidelines on surgical 
vs percutaneous management, there are similarities in how we can evaluate the efficacy of our 
management of these sub-categorizations of CAD. The APPROACH database offers an excellent 
opportunity to complete this goal and is the foundation of this project.   
  The original design of this project was to evaluate mortality outcomes in patients with 
low-risk triple vessel disease only. However, the course of this project offered the opportunity to 
additionally evaluate outcomes in the isolated LMCA population. Thus, the retrospective cohort 
design was the same in both studies; however, the MVD study revealed a much larger cohort of 
patients to work with. As such, a more detailed comparison was possible between 
revascularization strategies in the MVD population. As more patients are undergoing PCI now 
than the early stages of this database, more data becomes available for robust comparison. 
Nonetheless, the CABG cohort comprised the dominant strategy in both studies and we were 
able to assess some outcomes within this cohort based on differences in surgical strategy.  
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Notably, we were able to assess the BIMA vs SIMA graft strategy with regards to early and long-
term mortality. The results from this project show that our centre is comfortably using the BIMA 
strategy in both isolated LMCA and MVD populations, while producing excellent outcomes with 
respect to post-operative mortality in the short and long term. In fact, the results from this study 
suggest that further analysis of the BIMA grafting strategy is warranted. There are excellent 
numbers in the APPROACH database to create a follow-up retrospective cohort study, with a 
similar design to this one, that will produce meaningful results for our patient population.   
  The two research studies completed through this project also reflect the operator 
experience for both our cardiovascular surgeons and interventional cardiologists. This project 
allowed us to review our intra-operative and post-operative outcomes and complications from a 
quality assurance point of view. We were able to evaluate intra-procedural variables, such as 
infection, stroke, graft failure rates, etc., although not as the primary focus of this project. The 
quality assurance aspect of this project is valuable in evaluating our management strategies and 
clinical decisions at this centre, especially given that fact that the entire population of NL is 
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4.2 Limitations  
This retrospective cohort study is designed to evaluate revascularization strategies in two 
separate sub-categories of patients with CAD. The APPROACH database has the benefit of 
prospectively collecting and coding clinical data relevant to our research question. However, this 
project design has limitations.   
Firstly, APPROACH does not contain SYNTAX scores for patients, which take into 
account the precise anatomical complexity of a given patient’s lesion on a standardizing scoring 
system. Although these patients are reviewed on a case-by-case basis at interdisciplinary 
cardiovascular team rounds, there is no formal scoring system utilized for the patient population. 
Despite not obtaining a standardized and objective risk assessment for this population, they are 
required to be of a low complexity of disease by design in order to be included in the cohort. 
Secondly, the retrospective study design of this project introduces an inherent selection bias and 
information bias when collecting and analyzing data. Patients are selected for this study based on 
an outcome they have already experienced. Propensity score matching and logistical regression 
methods are used to address these biases; however, a prospective randomized controlled trial 
would be the best option to minimize these biases. Thirdly, the data analyzed in this study over a 
nine-year span is subject to changes in the operator experience over that same time frame. The 
literature has evolved significantly over the years and that has been reflected in updated clinical 
practice (Appendix A). Perhaps the most obvious example of this evolution is demonstrated in 
the changes in numbers of patients receiving PCI, especially in the MVD population. Despite 
these limitations, there remains value to publishing this research.   
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4.3 Advantages  
The project has offered the opportunity to conduct a detailed analysis of patient outcomes 
in both cardiovascular surgery and interventional cardiology. Moreover, it has offered insight 
into the level of detail and effort required to maintain a clinical database. The APPROACH 
database has been collected prospectively since 2006 and has provided an excellent opportunity 
to evaluate outcomes in specific patient populations, as discussed at length in this project. 
Additionally, it has created an outlook on the challenges of obtaining clinical data for research 
purposes. Robust inclusion and exclusion criteria were important factors in answering our 
research question. The primary benefit of the APPROACH database was allowing us to select a 
specific patient population to analyze outcomes in, which ultimately lead to being able to provide 
a benchmark for medium volume centres similar to ours. Clinical databases similar to  
APPROACH are excellent for providing real-world information on patients that are being treated 
in our medical system. Evaluating outcomes as a whole population provided the opportunity to 
assess where our local management practices align next to larger-scale guidelines and global 
practice. Despite the inherent selection bias with operating a retrospective cohort study, the 
upside was that it allows evaluation of what has been done and where local practice is trending 
towards. The results of this project have demonstrated several conclusions about CAD 
management.  
Firstly, the results showed that CABG represented the most common form of 
revascularization for isolated LMCA disease in this single centre with excellent short and 
midterm morbidity and mortality. We believe that the results of this first study can be expanded 
and used as a benchmark for other small-moderate volume centres. Furthermore, the BIMA 
grafting strategy can be effectively used with excellent outcomes, especially in patients younger 
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than 65. Secondly, this project evaluated if there were significantly different mortality rates in 
low-risk triple vessel disease patients treated by complete revascularization via either CABG or 
PCI. The results of the second study showed that there were no significant differences in 
mortality rates for this subset of patients receiving either CABG or PCI as a revascularization 
option. However, there have been fewer patients receiving PCI (n=45) as an intervention for 
complete revascularization of MVD than there are patients receiving CABG for the same 
indication (n=1559). The APPROACH database also revealed that the number of PCI patients are 
growing for this sub-population, reflecting a global trend in practice. Thus, future evaluation is 
warranted as the changes in clinical practice guidelines continue. Ultimately, we conclude that 
there was certainly a trend towards better long-term survival in the CABG cohort of patients; 
however, the number of patients receiving PCI continued to grow and it has become a viable 
option for the revascularization of low-risk triple vessel disease. Our morbidity and mortality 
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4.4 Lessons Learned  
This project has yielded insight into the complexities of developing sound research 
methodology. The realities of a prospectively collected database include difficulties in obtaining 
clean data representing the precise research question we have sought out to answer. Firstly, the 
APPROACH database started as a pilot project in 2006 (in NL) and has evolved in collection 
standards since that time. Several aspects of the database tend to be clinician-dependent and as a 
result, there were often key data-points missing. In this scenario, a more detailed chart review is 
necessary to obtain further information. In the context of this project, a significant amount of 
time was spent cleaning up the data provided to us from our initial capture. Key-word searches 
were able to identify the patients who were eligible for this study; however, at times a more 
detailed chart review within the APPROACH database was necessary to obtain missing data 
points. This was a process that consumed much of the data-collection phase of this study. The 
PCI cohort in particular was difficult to identify because of the nature of how the data was stored. 
Thus, for these patients they had to be identified by complete revascularization in all three 
territories and then retrospectively identified by their cardiac catheterization date and 
accompanying information. This was opposed to the CABG cohort that could be identified by 
having triple vessel disease on cardiac catheterization and then followed forward until they were 
chosen for CABG. Nonetheless, this project has identified an important need to maintain clean 
clinical databases that can be used for the purposes of identifying gaps in current literature. The 
journey of cleaning up the data for this project presented great insights into managing and 
researching with a clinical registry. The advice I can offer to future students undertaking a 
similar project is a clinical registry may not always have the exact information you are searching  
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for in order to answer a given research question; however, working with and cleaning up what 
you have is a vital component to successfully completing a research project.     
  
4.5 Conclusion  
This project was completed in partial requirement for the M.Sc. program in Clinical 
Epidemiology, within the Faculty of Medicine at Memorial University of NL. Throughout the 
course of this research, I have gained the opportunity to survey and summarize literature, design 
a retrospective cohort study, and complete data collection and analysis of clinical information. 
Furthermore, I have been able to develop the competencies to write this thesis throughout the 
course of the Clinical Epidemiology M.Sc. program. This project has offered its challenges; 
however, the conclusions drawn may provide input during interdisciplinary rounds and hopefully 
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Appendices  
Appendix A: Literature Summary Table   
The following is a summary of the major RCT studies published regarding MVD treatment. All 
cells in green indicate a significant difference in favor of CABG (unless marked by *, which 
means a significant advantage for PCI), all cells in red indicate a non-significant difference, and 
all cells in yellow indicate that particular outcome wasn’t measured. 
  
  
Primary Sig? = Was the 
primary outcome significant  
at alpha = 0.05  
MAC(C)E = Major adverse  
Cardiac (or Cerebrovascular) 
Events  
MI = Myocardial Infarction  NS = Not Significant  
Repeat = Repeat 
Revascularization  
N/A = Outcome Not 
Assessed  
All-cause = Mortality from 
all causes  
Cardiac = mortality from 
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